

CITATION REPORT

List of articles citing

ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety

DOI: 10.1097/ftd.ob013e3181858ca9

Therapeutic Drug Monitoring, 2008, 30, 628-33.

Source: <https://exaly.com/paper-pdf/45049675/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
56	Serum concentrations of paliperidone versus risperidone and clinical effects. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 797-803	2.8	33
55	The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 1109-17	2.8	72
54	Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice. <i>Pharmaceutics</i> , 2010 , 2, 258-274	6.4	8
53	Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. <i>Journal of Psychopharmacology</i> , 2010 , 24, 987-94	4.6	21
52	P.3.c.019 Community treatment orders and psychotropic medication: baseline data analysis for a one year follow up study (N= 200). <i>European Neuropsychopharmacology</i> , 2010 , 20, S468-S469	1.2	
51	P.3.c.020 Olanzapine in serum and cerebrospinal fluid in patients with schizophrenia or schizoaffective disorder. <i>European Neuropsychopharmacology</i> , 2010 , 20, S469	1.2	
50	P.3.c.021 Intramuscular aripiprazole versus injectable haloperidol in treatment of acute psychotic agitation. <i>European Neuropsychopharmacology</i> , 2010 , 20, S469-S470	1.2	4
49	Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 659-66	2.9	72
48	High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 4-9	1.7	34
47	Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. <i>Current Drug Targets</i> , 2011 , 12, 631-46	3	50
46	Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. <i>British Journal of Pharmacology</i> , 2011 , 164, 433-43	8.6	38
45	Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67, 47-54	2.8	38
44	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. <i>Pharmacopsychiatry</i> , 2011 , 44, 195-235	2	641
43	Relationship between P-glycoprotein and second-generation antipsychotics. <i>Pharmacogenomics</i> , 2011 , 12, 1193-211	2.6	83
42	Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). <i>Drug Metabolism and Pharmacokinetics</i> , 2012 , 27, 85-105	2.2	113
41	Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. <i>Pharmacogenomics Journal</i> , 2012 , 12, 255-9	3.5	29
40	Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012 , 39, 329-41	2.7	22

39	Analysing molecular polar surface descriptors to predict blood-brain barrier permeation. <i>International Journal of Computational Biology and Drug Design</i> , 2013 , 6, 146-56	0.4	45
38	Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. <i>International Review of Psychiatry</i> , 2013 , 25, 509-33	3.6	54
37	Pharmacogenomics can improve antipsychotic treatment in schizophrenia. <i>Frontiers of Medicine</i> , 2013 , 7, 180-90	12	22
36	Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. <i>International Review of Psychiatry</i> , 2013 , 25, 554-71	3.6	50
35	Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 289-98	1.7	19
34	Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 411-4	1.7	19
33	Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. <i>Pharmacogenomics Journal</i> , 2013 , 13, 197-204	3.5	18
32	Pharmacogenetics of second-generation antipsychotics. <i>Pharmacogenomics</i> , 2014 , 15, 869-84	2.6	20
31	Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort. <i>Applied & Translational Genomics</i> , 2015 , 5, 40-6		6
30	Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 709-35	6.2	158
29	Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5. <i>Human Psychopharmacology</i> , 2016 , 31, 93-102	2.3	5
28	Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 175-84	2.8	35
27	Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017 , 27, 185-191	2.9	21
26	Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017 , 121, 316-324	3.1	15
25	Association of ABCB1 C3435T polymorphism with the susceptibility to osteonecrosis of the femoral head: A meta-analysis. <i>Medicine (United States)</i> , 2017 , 96, e6049	1.8	8
24	Hyperprolactinemia with low dose of risperidone in a young female. <i>Asian Journal of Psychiatry</i> , 2017 , 27, 69-70	6.7	3
23	Advancing psychiatric pharmacogenomics using drug development paradigms. <i>Pharmacogenomics</i> , 2017 , 18, 1459-1467	2.6	4
22	ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting. <i>Human Psychopharmacology</i> , 2018 , 33, e2644	2.3	5

21	Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018 , 122, 596-605	3.1	32
20	Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018 , 123, 474-485	3.1	31
19	The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. <i>Pharmacogenomics Journal</i> , 2018 , 18, 422-430	3.5	27
18	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. <i>Pharmacopsychiatry</i> , 2018 , 51, 9-62	2	473
17	Could polymorphisms in ABCB1 gene represent a genetic risk factor for the development of mammary tumors in dogs?. <i>Veterinary Journal</i> , 2019 , 248, 58-63	2.5	1
16	The role of pharmacogenomics in adverse drug reactions. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 407-442	3.8	31
15	Risperidone-Induced Obesity in Children and Adolescents With Autism Spectrum Disorder: Genetic and Clinical Risk Factors. <i>Frontiers in Pharmacology</i> , 2020 , 11, 565074	5.6	4
14	Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1069-1081	3.8	10
13	ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 104, 110042	5.5	6
12	Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics. <i>Pharmaceutics</i> , 2021 , 13,	6.4	0
11	Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 109, 110241	5.5	0
10	Therapeutic Drug Monitoring in Neuropsychiatric Disorders. 2020 , 1-11		1
9	How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. <i>Frontiers in Genetics</i> , 2020 , 11, 491895	4.5	10
8	Antipsychotics and Cardiac Side Effects. 2019 , 1-10		
7	Antipsychotics and Cardiac Side Effects. 2020 , 721-729		
6	Therapeutic Drug Monitoring in Neuropsychiatric Disorders. 2020 , 753-763		
5	Pharmacogenomics and antipsychotics: efficacy and adverse drug reactions. 2022 , 161-188		0
4	Integrative analyses of genes related to femoral head osteonecrosis: an umbrella review of systematic reviews and meta-analyses of observational studies.. <i>Journal of Orthopaedic Surgery and Research</i> , 2022 , 17, 182	2.8	0

3 Table1_v1.DOCX. 2020,

2 An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use. 2022, 12, 270-281

0

1 Understanding inter-individual variability in pharmacokinetics/pharmacodynamics of aripiprazole in children with tic disorders: Individualized administration based on physiological development and CYP2D6 genotypes. 13,

1